To assess the association between neonatal SARS-CoV-2 antibody level at delivery andinfant COVID-19 infection under age 6 months, and to identify predictive factors forneonatal antibody level at delivery.
This prospective observational study was conducted at the Rabin Medical Center, Israel.
Mothers were enrolled from September 2021 to mid-February 2022, prior to transfer to the
delivery room, and followed at the Maternity and Infant Ward. The study was approved by
the institutional ethics committee (RMC- 0275-21). Written informed consent was obtained
from the participating mothers. Inclusion criteria included maternal recipient of at
least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed
natural COVID-19 infection. Exclusion criteria included (a) preterm birth at <34 weeks
gestation; (b) congenital or acquired immune deficiency, including recipient of
biological agents during the prior year to enrolment.
Other: no intervantion
no intervention
Inclusion Criteria:
included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or
prior microbiologically-confirmed natural COVID-19 infection
Exclusion Criteria:
(a) preterm birth at <34 weeks gestation; (b) congenital or acquired immune deficiency,
including recipient of biological agents during the prior year to enrolment.
Schneider Children's Medical Center
Petach Tikva, Israel
Liat Ashkenazi-Hoffnung, Principal Investigator
Schneider children medical center